Close

Calithera Biosciences (CALA) Granted License to TransTech's Hexokinase II Inhibitor

March 5, 2015 4:51 PM EST Send to a Friend
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login